Inclusion Criteria:

          -  Histologically confirmed non-small cell lung cancer (NSCLC) with PTK7-expressing tumor
             using an immunohistochemistry (IHC) assay previously validated at a designated
             laboratory

          -  Recurrent NSCLC that has progressed after treatment with at least the following
             approved therapies with demonstrated clinical benefit: a platinum-based chemotherapy
             doublet and an immune checkpoint inhibitor for tumors without targetable genetic
             alterations; a platinum-based chemotherapy doublet and targeted agent(s) for tumors
             with targeted genetic alterations

          -  Received ≤ 2 prior lines of systemic therapy, including no more than 1 line of
             systemic cytotoxic chemotherapy (≤ 3 prior lines for tumors treated with targeted
             agent(s) for genetic alterations, including no more than 1 line of systemic
             chemotherapy)

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1

          -  Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version
             1.1

          -  Adequate bone marrow, renal, and hepatic function per the protocol

        Exclusion Criteria:

          -  Known uncontrolled metastases to the central nervous system (CNS). Participants with
             CNS metastases may be eligible provided that definitive therapy has been given, and
             participants are asymptomatic and off systemic steroids and anticonvulsants used for
             management of brain metastases for at least 2 weeks prior to the first dose of study
             drug

          -  Unresolved clinically significant adverse events Grade ≥ 2 from prior anticancer
             therapy (with the exception of alopecia or anemia)

          -  Has clinically significant medical condition(s) as described in the protocol

          -  Received anticancer therapy including chemotherapy, radiation therapy, immunotherapy,
             biologic, or any investigational therapy within 28 days prior to the first dose of
             study drug (no washout period required for participants on EGFR tyrosine kinase
             inhibitors). Palliative radiation therapy for bone, skin or subcutaneous metastases
             with 10 fractions or less is not subject to a washout period

          -  Received anti-cancer herbal therapies within 7 days prior to the first dose of study
             drug